GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 12:48:26 30/04/2024 BST			5-day change	1st Jan Change
1,668 ^GBX	-0.13%		+1.24%	+15.26%

04-29	GSK : UBS reaffirms its Buy rating	ZD
04-29	Hipgnosis Songs Fund backs new Blackstone bid	AN

Evotec SE acquired Campus Levi-Montalcini from GlaxoSmithKline plc for € 1.

July 30, 2021

Evotec SE (XTRA:EVT) acquired Campus Levi-Montalcini from GlaxoSmithKline plc (LSE:GSK) on July 1, 2021.

Evotec SE (XTRA:EVT) completed the acquisition of Campus Levi-Montalcini from GlaxoSmithKline plc (LSE:GSK) for € 1 on July 1, 2021.

Latest news about GSK plc

GSK : UBS reaffirms its Buy rating	04-29	ZD
Hipgnosis Songs Fund backs new Blackstone bid	04-29	AN
Sector Update: Health Care Stocks Drop in Afternoon Trading	04-25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	04-25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	04-25	MT
GSK Files Lawsuit Against Pfizer, BioNTech Over mRNA Patents Infringement	04-25	MT
Moody’s Affirms Haleon’s Ratings on Strong Operating Performance	04-25	MT
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	04-24	MT
Global markets live: Heineken, AT&T Hasbro, Visa, Boeing...	04-24
GSK's Application for Jemperli's Expanded Indication Accepted by FDA for Priority Review	04-24	MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	04-24	MT
GSK : Gets a Sell rating from JP Morgan	04-24	ZD
GSK : Gets a Buy rating from Bernstein	04-24	ZD
GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli	04-24	CI
GSK: FDA priority review for endometrial cancer	04-24	CF
GSK's Jemperli with chemotherapy accepted for priority review by FDA	04-24	AN
GSK Secures US FDA's Priority Review for Expanded Use of Endometrial Cancer Treatment	04-24	MT
GSK Says U.S. FDA Accepts New Indication Filing For Jemperli	04-24	RE
Edwards Lifesciences Corporation: The story continues	04-23
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	04-22	MT
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	04-17	MT
GSK: positive clinical results for gonorrhea	04-17	CF
Gsk plc Announces New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than A Decade	04-17	CI
GSK: shingles virus effective for over 10 years	04-17	CF
GSK hails data on Shingles vaccine and gonorrhoea treatment	04-17	AN

Chart GSK plc

Duration

Period

More charts

Company Profile

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Sector

Pharmaceuticals

Calendar

29/04/2024 - European Society of Clinical Microbiology and Infectious Diseases Meeting

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK PLC : 2023 ended on a strong note; medium- to long-term guidance raised

February 02, 2024 at 02:40 pm

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.7 GBP

Average target price

20.06 GBP

Spread / Average Target

+20.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+15.26%	85.64B
ELI LILLY AND COMPANY	+26.47%	664B
NOVO NORDISK A/S	+30.54%	567B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.35%	330B
ABBVIE INC.	+4.23%	286B
ASTRAZENECA PLC	+14.45%	234B
NOVARTIS AG	+4.98%	199B
ROCHE HOLDING AG	-10.10%	196B
AMGEN INC.	-4.04%	148B

Other Pharmaceuticals

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Evotec SE acquired Campus Levi-Montalcini from GlaxoSmithKline plc for € 1.

EPS Revisions